Evidence map›Paper›PMID 42465799›Full record

ArticleResearch (Washington, D.C.)2026

M2 Macrophages Attenuate AQP2

Liang Tang, Zhangcheng Liao, Meng Gao, Minghui Liu, Yongchao Li, Jian Wu, Hao Yu, Cheng He, Feng Zeng, Jinbo Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Liang TangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhangcheng LiaoDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Meng GaoDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Minghui LiuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yongchao LiDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jian WuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hao YuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cheng HeDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Feng ZengDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jinbo ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hequn ChenDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zewu ZhuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID https://orcid.org/0000-0001-5320-9391

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcium oxalate (CaOx) kidney stones are common and recur frequently, yet effective pharmacological prevention is limited. Randall's plaques (RPs), calcium deposits on renal papillae, act as anchoring sites for CaOx crystal growth, but the cellular origin and immunoregulatory mechanism underlying early calcium deposition remain unclear. Here, we found that early calcium deposition was partially localized to the renal interstitium surrounding aquaporin 2 (AQP2)-labeled collecting duct cells with apoptotic phenotype, and inhibiting high calcium-induced apoptosis of AQP2

Identifiers

PMID42465799
PMCPMC13373320

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.